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ORIGINAL ARTICLE
Development and preliminary evaluation of a clinical
guidance programme for the decision about prophylactic
oophorectomy in women undergoing a hysterectomy
I Pell, J Dowie, A Clarke, A Kennedy, V Bhavnani
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Objectives: To develop a decision analysis based and computerised clinical guidance programme
(CGP) that provides patient specific guidance on the decision whether or not to undergo a prophylac-
tic oophorectomy to reduce the risk of subsequent ovarian cancer and to undertake a preliminary pilot
and evaluation.
Subjects: Women who had already agreed to have a hysterectomy who otherwise had no ovarian
pathology.
Setting: Oophorectomy decision consultation at the outpatient or pre-admission clinic.
Methods: A CGP was developed with advice from gynaecologists and patient groups, incorporating
a set of Markov models within a decision analytical framework to evaluate the benefits of undergoing
a prophylactic oophorectomy or not on the basis of quality adjusted life expectancy, life expectancy,
and for varying durations of hormone replacement therapy. Sensitivity analysis and preliminary testing
of the CGP were undertaken to compare its overall performance with established guidelines and prac-
tice. A small convenience sample of women invited to use the CGP were interviewed, the interviews
were taped and transcribed, and a thematic analysis was undertaken.
Results: The run time of the programme was 20 minutes, depending on the use of opt outs to default
values. The CGP functioned well in preliminary testing. Women were able to use the programme and
expressed overall satisfaction with it. Some had reservations about the computerised format and some
were surprised at the specificity of the guidance given.
Conclusions: A CGP can be developed for a complex healthcare decision. It can give evidence-based
health guidance which can be adjusted to account for individual risk factors and reflects a patient’s
own values and preferences concerning health outcomes. Future decision aids and support systems
need to be developed and evaluated in a way which takes account of the variation in patients’ prefer-
ences for inclusion in the decision making process.
Providing individual patients with decision support toallow them to take a fuller part in treatment decisions—ifand how they wish—is likely to become an increasingly
important component to improving quality in health care.
Patient involvement in decision making increases adherence
to treatment choices and improves satisfaction and the appro-
priateness of interventions.1 2 It is clear that many patients
both value and are able to make use of enhanced information
about treatments and treatment choices. A variety of methods
of delivering enhanced evidence-based patient information
have accordingly been developed, including leaflets, decision
boards, audiotapes, videotapes, interactive laser disks, and
computer programs.3–5 Despite these developments, the
presentation of research based information to patients, and
especially recommendations, is still rare in practice and the
practical difficulties involved are considerable.
Not unconnected with these difficulties is legitimate
concern about the rate at which high quality research findings
enter clinical practice, independent of any consideration of
informing patients. Until now the main approach to dissemi-
nating best practice more effectively throughout the medical
community has been the development of expert based guide-
lines. However, standard written guidelines cannot hope to
cover the range of inputs and potential outcomes that need to
be taken into account for a specific patient, even when
management of a common condition is the focus.Nor can they
respond to individual patient preferences in relation to health
outcomes in the rigorous way that is provided in relation to
clinical evidence.
Our aim was to address these issues simultaneously
through the development of a computerised clinical guidance
programme (CGP) based on broad decision analytical
principles which would integrate research based evidence
(adjusted for individual patient risk factors) and patient pref-
erences in order to arrive at an explicit recommendation. All
the assumptions and evidence underlying the recommen-
dation would be accessible on request. The prototype CGP
described here has been developed in the context of
prophylactic oophorectomy (PO).
BACKGROUND
Prophylactic oophorectomy (PO)
Women who have decided to undergo a hysterectomy face, in
the absence of compelling clinical indications, a further deci-
sion as to whether or not to have concurrent PO. This is a sur-
gical operation to remove the ovaries as a prophylactic proce-
dure against ovarian cancer. The decision, although apparently
straightforward, is a complex one. Expert opinions on the
appropriateness of PO vary and there is considerable variation
in practice. In the UK in 1989, 20% of gynaecologists said they
would routinely remove the ovaries of premenopausal women
aged 45–49 years in the course of hysterectomy and 51% said
they would do so in the case of premenopausal women aged
over 49 years.6 The annual incidence of ovarian cancer in the
UK is 1/3800 in women aged over 25 and 1/2500 in those aged
over 55, with a lifetime risk estimated at 1.5–2%. Estimates of
the proportion of ovarian cancers potentially prevented by use
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of PO vary between 1% and 11%.7 8 The complexity of the deci-
sion whether or not to undergo PO lies in the relative rarity of
ovarian cancer coupled with the multiple indirect effects of
removing the ovaries. While surgical removal effectively
precludes the development of ovarian cancer, it creates
indirect effects on other body systems through the cessation of
oestrogen production, with notable effects on the chances of
developing breast cancer, osteoporosis and osteoporosis
related fractures, and heart disease. Taking supplemental oes-
trogen in the form of hormone replacement therapy (HRT)
can modify these indirect effects to some extent. The decision
therefore depends on a number of factors relating to the indi-
vidual clinical characteristics of the patient and her family
history, on the values she attaches to a number of different
disease states of varying severity, and on her views on and
anticipated compliance with HRT. The patient is faced with the
task of making a set of trade offs involving the direct and
indirect effects of the decision. It is doubtful if the unaided
patient or clinician is capable of making these complex trade
offs intuitively. Certainly, in their survey of PO, Jacobs and
Oram6 found that most gynaecologists were using a simple age
related rule. It did not appear that important competing out-
comes or the influence of personal or family history were
being taken into account in any explicit way. This finding,
coupled with the evident complexity of the decision, suggests
that modelling the decision may be one obvious solution.
Decision analytical techniques
Decision analytical techniques have typically been seen as a
suitable basis for guideline and clinical policy development,
and rarely envisaged as being directly applicable in the clinical
situation to help clinician and patient working together to
make the optimal decision for that individual. However, they
are useful if patients and clinicians value analysis based con-
clusions about their treatment, systematic exploration of their
relevant preferences, and if either the patient, doctor, or both
would like instant access to research based information about
their choices and possible outcomes. Decision analytical mod-
els provide the technology required, enabling the patient and
clinician to examine all aspects of the decision explicitly and
transparently.9
METHODS
System design
The clinical guidance programme (CGP) is based on a set of
Markov cycle tree models10 which allow for net benefit or loss
from PO to be calculated under varying durations of HRT.
There is oneMarkovmodel for each of the four main outcomes
affected by the PO decision: cardiovascular disease, breast
cancer, osteoporosis related major fracture, and ovarian
cancer.
A Markov model is designed so that a hypothetical patient
population—all with the characteristics of the individual
under consideration—is taken through a predetermined
number of cycles (a year long in our case). Each individual is
always in one of a set of exclusive states during a cycle. For
example, in the cardiovascular disease model the component
diagnostic states (defined as disease states that can be
uniquely identified using the WHO ICD10 taxonomy) were
“well”, “angina”, “myocardial infarction”, and “dead”.
Whether an individual stays in his or her current state or
switches to a different state is defined by an (evidence-based)
transition probability—for example, the probability of a
woman who is previously “well” developing angina. The
experience of this hypothetical population as it progresses
through a series of annual cycles gives us the expected outcome
of an intervention for an individual, calculated as evidence-
based life expectancy (LE) given the characteristics of the
individual under consideration.
It should be noted that the CGP deals implicitly with multi-
ple states whereby an individual with ovarian cancer might
also have a hip fracture because the results of all four Markov
models are used to derive the final figures for LE, but it is
assumed that the condition specific transition probabilities are
not affected by the occurrence of multiple states.
Apart from LE, the CGP also calculates the net benefit of (or
loss from) oophorectomy as quality adjusted life expectancy
(QALE). In order to undertake the “quality adjustment” of LE,
each period of time spent in each diagnostic state (cycle) is
multiplied by the utility of being in that state for each of the
Markov models. We therefore needed to map each diagnostic
state (for example, angina) on to a set of health states, those
of the generic multidimensional index EQ-5D.11 12 We found no
usable empirical mappings for our diagnostic states and
therefore used consensus estimates from 10 healthy volun-
teers (including doctors, postgraduate students, and research-
ers in health related fields). They were asked to use their
awareness and personal experience to assess the percentage of
time they considered a patient in each of the relevant
diagnostic states would spend at a particular level on each of
the EQ-5D dimensions (pain, mobility, etc). The CGP applies a
woman’s individual quality adjusted values, explicitly elicited
by the program, to the relevant health states she will pass
through (fig 1), thus ensuring that the QALE reflects her out-
come preferences. If a woman finds the process of having her
preferences elicited either too difficult or too time consuming,
the model allows her to elect to use standard health state
valuations derived from published tariffs resulting from a
population survey.12
Information requirements
To perform the relevant calculations the CGP requires
information regarding both clinical factors and patient prefer-
ences. This is obtained from the literature (incidence,
mortality, and relative risks) and from the patient (age,
personal risk factors, and attitude to risk).
Evidence from the literature
Evidence from the literature was obtained by systematic
searching of Medline, BIDS/Embase, and the Cochrane Data-
base of Systematic Reviews for each major outcome and key
risk factors in relation to four interventions: hysterectomy
with oophorectomy with and without subsequent HRT and
hysterectomy alone with andwithout HRT. The search strategy
was based around the retrieval of relevant systematic reviews
with as high a level of sensitivity and precision as possible,
using a variety of free text methodological terms. It was also
designed to ensure that randomised controlled trials and large
scale epidemiological observational studies were included.
Major outcomes included were coronary heart disease, breast
cancer, ovarian cancer, and osteoporosis. Risk factors included
were family history, smoking, parity, age at menarche, and
exercise levels. Back searching and hand searching of articles
was undertaken to ensure that relevant material (systematic
reviews or large scale randomised or observational studies)
were included. Incidence and survival data for the major out-
comes for women in the appropriate age groups were obtained
from a number of sources, principally the Office of National
Statistics, the US National Cancer Institute, the Surveillance,
Epidemiology and End Results (SEER) database, the Ameri-
can Heart Association, and relevant previous analyses.13 14 Two
authors (AC, AK) assessed studies for use. In order to be
included, publications had to have relevant subjects, interven-
tions, and outcomes. Data were gathered using a hierarchy of
evidence (meta-analysis, systematic review, randomised con-
trolled trial, prospective observational study). Evidence was
collected for all four conditions and for each diagnostic
state—for example, for coronary heart disease we gathered
evidence on the effect of PO, HRT, and relevant risk factors on
the incidence of angina and myocardial infarction.
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Patient information
Patient information was obtained during the running of the
CGP in a number of stages. The patient was first asked for her
name (or other unique identifier), age, and relevant risk
factors such as smoking habits, family history of breast and
ovarian cancer, or previous osteoporotic fracture. The various
outcomes of the decision are heavily influenced by the
hormonal status of the patient, whatever the decision on
oophorectomy. Since this status is altered if the patient takes
HRT, the patient was asked about her (provisional) intentions
toward this therapy under each option. (Because the time
period for taking HRT is self-selected, the model assumes
100% concordance with these intentions in its baseline result
but a sensitivity analysis provides the patient with the results
for a wide range of durations.) In order to individually tailor
the output from the model, the patient was asked to indicate
her risk preference (by a single health related standard gam-
ble item) and to rate a number of health states using the
standard “time trade off” method. In this step (and after
explanation and a trial run), the woman was asked to say how
many years of normal health she would be prepared to give up
in order to be free of a particular combination of factors
affecting her health such as reduced mobility and moderate
pain. (Alternative configurations using the standard gamble
and visual analogue scale approaches are built in but were not
used in this pilot.)
At most stages the patient could opt out to default (popula-
tion based) values if she wished, although she was always
asked to confirm that she understood that the final results
would potentially be less tailored to her own values than they
would otherwise have been.
Calculations
For each of the four conditions (ovarian cancer, breast cancer,
cardiovascular disease, and osteoporosis related major frac-
ture) the number of years the patient is expected to spend in
each specific diagnostic state under the oophorectomy option
was calculated and added to produce LE values for each con-
dition. For quality adjustment, the individual times spent in a
diagnostic state weremultiplied by the patient’s values for that
diagnostic state and added to produce individualised QALE
measures for each condition. This process was repeated using
the same set of patient values and risk factors, but this time
adjusting the probabilities to reflect the expected conse-
quences of the no oophorectomy option. The difference
between the results for the two interventions was presented in
the form of a guidance statement (fig 2). This always favours
the option with the higher average QALE, irrespective of the
size of the difference. The results were presented to three deci-
mal places to allow for small differences such as a few “qual-
ity adjusted life weeks” to be shown.
All the numbers underlying the various results are available
in a series of increasingly detailed screens if requested by the
patient or her physician. A sensitivity graph then allows the
woman to see the effect of any change from her provisionally
expressed intention in relation to HRT. Finally, the programme
produces a full report of the consultation, which may be
printed out for the patient or physician to take away and
study. If requested, a pictorial representation of the gains and
losses by condition can also be printed (fig 3). The report is
automatically updated if the patient returns to the programme
to revise any of her inputs, and the programme can be rerun
with changed inputs if the patient so wishes.
Figure 1 Structure of the clinical
guidance programme. LE = life
expectancy.
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Figure 2 Summary results screen.
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Patient and clinician input into the design process
Women in the appropriate age range from three community
groups in southern England and the Midlands (two hysterec-
tomy support groups and one non-health related group) were
invited and agreed to help in the design process. Focus groups
were held with each group before the CGP was designed to
elicit key topic areas of importance for inclusion. The focus
groups were taped and transcribed and a thematic analysis
was undertaken. Preliminary versions of the CGP were piloted
with each group and comments were noted in detail. A
number of amendments were made to the programme in
response to these comments. The CGP was also demonstrated
at a number of meetings with gynaecologists in the study
hospitals, their comments were noted, and amendments were
made to the CGP in response.
Preliminary testing of the CGP
A sensitivity analysis was undertaken, varying assumptions
about the effects of quality adjustment, and the anticipated
guidance from the CGP was compared with published guide-
lines and with actual practice in the UK using a prospective
dataset of 16 000 women undergoing hysterectomy in the UK
in 1994/5 (A Metcalfe, K McPherson, personal communica-
tion).
Preliminary piloting of the CGP
Approval to administer the CGP and to undertake in-depth
qualitative interviews was obtained from the NHS Executive
London Regional Office (MREC) research ethics committee
and from the local research ethics committees of six
participating hospitals. A convenience sample of 19 women
recruited from six hospitals in south east England consented
to participate in the preliminary pilot study. All were about to
undergo hysterectomy with the possibility of undergoing
oophorectomy. Women were taken through the CGP with one
of the researchers acting as a facilitator (VB) and 10 women
then participated in semi-structured interviews. The inter-
views were transcribed and analysed independently by two
researchers (AC/VB) and a thematic analysis was undertaken.
RESULTS
Patient and clinician input to design process
Patient and clinician input to the design process resulted in a
number of changes to the CGP including revision of the
screens which explain the “time trade off” task, changing of
the word “hypertension” to “high blood pressure” throughout,
and the addition of an evidence base viewer. A major change
was addition of introductory screens with full explanatory
text for each task. These could be switched on or off at the
facilitator’s discretion.
Preliminary piloting
All the women were able to use the CGP with a facilitator.
During the preliminary pilots with patients the CGP took
between 10 and 25 minutes to run the programme (mean run
time 20 minutes) The run time depends largely on the extent
to which individual values are entered or default options used.
Results of the qualitative analysis are summarised in table
1. Patients were grateful for the time and attention paid to
their decision and overall satisfaction with the CGP was high.
There was some mistrust of computers and computer
programs and a feeling that a “human touch” was important.
Some women found the “time trade off” exercise initially dif-
ficult although most understood what was required after
being presented with one or two health states to value; some
reported that they found it difficult to think about “abstract”
health states.
The CGP is unusual in giving a very explicit guidance state-
ment and this appeared to be problematic, especially for
women who received advice which was discrepant with their
previously held intentions. However, the CGP appeared to
clarify the PO decision for most of the women.
Sensitivity analysis
By analysing the outputs from CGP simulation runs, the
results for any combination of the current data inputs were
established in the form of an equation (box 1).
Taking one extreme case (where all living diagnostic states
other than “well” are valued at 0—that is, all quality
adjustments at 0), the equation returns a net benefit of –0.523
QALE (about 27 quality adjusted weeks) so the patient inter-
ested only in disease free years should not undergo oophorec-
tomy. Taking the other extreme (where all living diagnostic
Figure 3 Condition comparison screen. This summary screen
shows the net benefits for a particular individual in undergoing
oophorectomy. Several points should be noted from the figure: (1)
benefits occur in three of the four major outcome conditions; (2) the
risk of ovarian cancer is reduced if the patient undergoes
oophorectomy; (3) as stated in the text, the patient has indicated
previously in the CGP that she will take hormone replacement
therapy (HRT) and the benefits of this are evident in reduction in the
risk of heart disease and major fractures; (4) the patient’s risk of
breast cancer is almost unchanged, but this is the net effect of a
combination of a reduction in risk due to oophorectomy coupled with
an increase in risk due to HRT; (5) the overall expected benefits are
small, although the output suggests a definite decision.
OK
1/4 1/40
Expected benefit (QALYs)
No Oophorectomy Oophorectomy
Ovarian cancer
Heart disease
Major fractures
Guidance value
Breast cancer
The Program, given what it has been told about you and
your preferences, favours the OOPHORECTOMY option.
This guidance is based on your stated intensions: to take
HRT after your oophorectomy for 8 years OR to take HRT
after your menopause for 2 years
Table 1 Summary of qualitative findings about clinical guidance programme
Expectations Clarification of decisions
Process of using decision aid Most tasks completed by most women. “Standard gamble” and “time trade off” exercises found most difficult because
of difficulty of thinking in the abstract
Reactions to the output Surprise at specificity of guidance
Impact on decisions Decision clarification, but not necessarily in line with guidance statement
Attitudes towards overall
presentation of decision aid
Overall satisfaction. Seen as offering “time to think and talk”. Some negative attitudes to the technology apparent
(“grey box”), but viewed as up to date
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states are valued at 100—that is, all quality adjustments at
1.0), the net benefit is +0.073 QALE (about 4 quality adjusted
weeks) so the patient who values living (in any state) equally
(and rates them all as good as full health) should undergo
oophorectomy. Between these hypothetical extremes the net
benefit can be calculated for any set of utilities elicited from
the patient.
Comparison of CGP with previous analyses and
published guidelines
Speroff et al13 studied the effects of non-compliance with pre-
scribed HRT. They modelled four strategies (PO with and
without HRT and natural menopause with and without HRT)
and found that, while perfect compliance always favours
oophorectomy, partial compliance changes the decision and
the CGP agrees with the full model strategy given in Speroff’s
paper. We assumed 100% concordance by women with their
own estimates of the duration of time for which they
anticipated taking HRT. However, we also included a graph in
the CGP itself which shows women the effects of changing the
duration of HRT and how sensitive the decision is (in their
particular case) to HRT duration.
Grann et al15 studied a population of BRCA1 or BRCA2
patients (who have a genetic predisposition to breast cancer)
and the potential gain to them of PO and/or mastectomy. To
this end they modelled breast and ovarian cancer in detail, but
did not incorporate any of the collateral effects of oophorec-
tomy, nor did they explicitly consider the effects of HRT. They
estimated that PO increased LE for a 30 year old subject by
0.4–2.6 years. A comparison with our result for a patient who
has one first degree relative with breast cancer shows that the
CGP calculates an increase of 1.6 life years with PO. However,
while this figure is right in the middle of the range reported by
Grann et al, the methods of obtaining health state values were
different and a comparison of absolute values is not possible.
Schrag et al16 also studied BRCA positive subjects and
reported a gain in LE of 0.5–1.5 years, depending on the prob-
ability of breast cancer and ovarian cancer. This again
compares with our figure of 1.4 years for a 30 year old subject.
On the basis of these published studies, the CGP appears to
provide guidance that is in line with, but not identical to, that
which can be derived from other published decision analyses.
Comparison with current practice and guidelines
Between the ages of 42 and 46 the proportion of women who
have both ovaries removed during hysterectomy rises from
approximately 30% to 60% (fig 4). The net expected benefit of
oophorectomy as calculated by the CGP was compared with
the reported proportion of PO in practice derived from a major
cohort study of women undergoing hysterectomy in the UK in
1994/5. A monotonic relationship between the two was found,
but this was non-linear. A good fit was obtained by log trans-
formation of the proportion of PO. Least squares linear
regression (net benefit versus loge observed proportion) gave
an adjusted r2 value of 0.953 (F 6.17e–11) for QALE. This result
suggests that the guidance produced by the CGP is closely
related to, but not synonymous with, current practice.
Discrepancies occur at around the age of 46 years where the
CGP suggests that the net benefit of PO tends to flatten off,
although in actual practice the proportion of POs undertaken
continues to rise.
The College of Physicians and Surgeons of Manitoba
published clinical guidelines on this topic in 199917 and the
CGP’s recommendations are also broadly in line with this
guidance.
DISCUSSION
We have developed a clinical guidance programme which
employs decision analytical techniques to model the conse-
quences of undertaking PO or not during a total abdominal
hysterectomy. The programme is based on research evidence
and supplies guidance in the form of an explicit statement
favouring one or other intervention, as well as detailed
numerical results and graphical representations. It draws on
the patient’s own risk factors and preferences for health state
outcomes. In this respect it is an innovation, combining indi-
vidual values and preferences with the research evidence to
produce individualised evidence-based guidance.
Piloting of the CGP showed that it is feasible to use in the
clinical context and is valuable in clarifying the decision. The
sensitivity analysis shows that quality adjustment is a
valuable addition in that it has the potential to “swing” the
decision one way or another. In none of our patients did the
QALE based recommendation actually differ from that which
would have been made by the LE result in terms of the sign of
the difference, although the size of the difference did vary
considerably in several cases.
The proportion of oophorectomies recommended by the
CGP at a population level is reasonably in line with that
produced by current practice. However, that should not neces-
sarily be regarded as a valid test since the CGP can improve the
appropriateness and quality of decisions at an individual level
through its ability to take account both of the evidence on all
relevant outcomes and of an individual’s risk factors and
values.
Limitations of the study
Why was a conventional decision tree not used? Decision trees
require that the outcomes at any chance node should be
mutually exclusive and collectively exhaustive. Thus, if the
Box 1 Equation derived from the CGP describing the
net benefit of oophorectomy
As an example, the equation for the net benefit of
oophorectomy for a 40 year old woman with no clinical
risk factors and planning to take no HRT whether or not she
undergoes PO is as follows:
Net benefit = 0.457(CHSV) – (1.04.U(OC))
+ 0.049(CHSV) – (0.025.U(BC))
– 0.252(CHSV) + (0.101.U(Ang)) + (0.014.U(MI))
– 0.777(CHSV) + (0.588.U(Spine)) + (0.022.U(Hip))
where CHSV = current health state valuation, U = utility
(e.g. in quality adjusted life years), OC = ovarian cancer,
BC = breast cancer, Ang = angina, MI = myocardial in-
farction, Spine = vertebral fracture, Hip = hip fracture.
Figure 4 Comparison of benefit (in QALYs) from hysterectomies
where oophorectomy is undertaken at different ages as predicted by
the CGP and proportion of hysterectomies where oophorectomy was
actually undertaken in the UK in 1995.
CGP: LE
CGP: QALY
Actual PO
30 32 34 36 38 46 47 48 49 50 51 52 60 65 7040 42 44
Age
1
0.8
0.6
0.4
0.2
0
_
0.2
_
0.4
_
0.6
_
0.8
Actual
proportion
PO
Net benefit of
PO in QALYs
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decision involves a number of non-exclusive outcomes, the
classic decision tree format becomes practically unworkable. A
further problemwith the classic formulation is that it takes no
account of time dependency in the probabilities. Converting
the model to a Markov cycle tree helps to solve this latter
problem, but this still requires that the transition probabilities
from any state represent mutually exclusive and exhaustive
transitions. One approach, used by Speroff et al13 in their earlier
decision analysis of the oophorectomy decision, is to create a
number of “combination states” and to model transitions
explicitly between combinations. We took an alternative
approach which seeks to cope with the exponential increase in
complexity by a combination of decomposition of the problem
into a number of diagnostic states and abstraction of these
into health states.
There is considerable discussion as to the relative value of
the “time trade off” approach which we used to establish
women’s individual diagnostic state valuations in order to
obtain QALE values.18 19 The CGP allows for these values to be
elicited by means of “time trade off”, reference lottery, or
visual analogue scale. Given that one of these must be chosen,
we selected “time trade off” for use in the pilot study mainly
because of the existence of “time trade off” based population
values that could be used as defaults.
Following the work of Cher et al,20 we included as a further
configuration option a one off, conventionally phrased standard
gamble item in the CGP that establishes the patient’s risk pref-
erence. (The patient is asked at what level she would accept a
treatment that has a chance of either returning her to perfect
health or results in death compared with no treatment which
would result in good health but for a shorter period of time.)
The resulting parameter is used to risk adjust “time trade off”
valuations before further calculation. The CGP reported here
does not incorporate costs, but it could very simply be extended
to incorporate a cost element and produce outcomes calculated
in terms of cost per unit of quality adjusted time.
A drawback of many guidelines and decision aids is that the
evidence base becomes outdated. One of the advantages of the
data structure used in the CGP is that it can easily be updated
to reflect new research findings. We see the programme as
dynamic rather than as a static product.
The explicit guidance produced by the CGP is both a
strength and a problem. The programme intentionally gives
very specific guidance in line with the inputs provided (and its
underlying assumptions), but it may cause problems if a
patient or clinician already holds a strong intention or
opinion. We need to undertake research to understand better
the optimal timing for decision aids such as the CGP so that
they can be used to their fullest potential as a readily available
“third opinion”.We see development of a more “user friendly”
interface as important in ensuring that both clinicians and
patients feel comfortable with the format.
CONCLUSIONS
We have developed a computerised clinical guidance pro-
gramme based on decision analytical techniques which mod-
els the consequences of health interventions, uses both the
available evidence and patient-specific information on risks
and preferences to provide guidance, and which has been suc-
cessfully piloted with a small number of patients. The decision
to perform an oophorectomy on women between the ages of
40 and 50 is controversial. By making explicit the assumptions
and evidence upon which its precise guidance is based, the
CGP makes it possible for the physician and patient to explore
in detail the trade offs and personal assumptions that will
affect the decision. Transparent as far as both principles and
data are concerned, the CGP can improve the quality and
appropriateness of a decision and could be regarded by doctor
and patient as an innovative and immediately available expert
opinion. The reactions of individual women to the CGP in this
pilot study suggest that work is required in future designs to
ensure a more “user friendly” interface. It will also be impor-
tant to take account of individual preferences for the extent
and type of desired participation in decision making.
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. . . . . . . . . . . . . COMMENTARY ... . . . . . . . . . .
Recent years have seen increasing emphasis on the patient
role in decision making and a move away from the traditional
paternalistic medical model.1 In 1980 a Medline search identi-
fied 213 papers with theMESH heading of “decision making”.
By 2000 this had risen to 2508 papers.
In 1993 a report of a working party on appropriateness of
patient care in QHC recognised the importance of effective
information exchange with patients and the central import-
ance of patient preferences in the choice of appropriate
interventions—that is, appropriateness is not purely defined
by technical elements of quality such as effectiveness, but also
by patient values and perceptions.2 Furthermore, there has
been increasing recognition that patient derived outcome
measures need to be incorporated alongside, or in place of,
traditional clinical or biochemically defined measures, both in
research and practice.3–5 Patients’ aspirations for the outcomes
of their health care may differ from those of their clinicians,
and increasing evidence suggests that patients’ preferences
and those of doctors differ.6
Internationally, the recognition of the changing role of the
patient is being reflected in health policy. The UK NHS puts
patient and public involvement at the core of recent health
policy—for example, recognising the patient as expert in his/
her condition, particularly in chronic diseases.7–10 The unsuc-
cessful review of health care initiated by Bill Clinton in the US
also put patient and public choice firmly at the centre, albeit in
a more market driven model.11 The future of high quality
health care can no longer be defined purely, or even substan-
tively, by professional providers: recognising and engaging the
patient is an ethical12 and practical necessity, but to do this
requires several important developments. Thus, doctors and
other clinicians need ready access to evidence-based infor-
mation in a form that can be clearly communicated to
patients.13 14 Furthermore, both patients and clinicians need to
be supported in developing new relationships within the
changing dynamic of the consultation.15 16
The two preceding papers17 18 come from our two separate
research groups and describe the development and piloting of
two computerised decision support tools. These projects were
separately initiated,with very similar aims, but targeted at two
quite different clinical conditions. Each set out to find a
mechanism of (1) communicating risks and benefits of treat-
ments clearly to patients who had to make a choice in the face
of uncertainty; (2) incorporating patient preferences and/or
values into the decision making process; and (3) bringing the
evidence base to bear upon such difficult decisions (to the
benefit of both the patient and the clinician).
Despite starting out with similar aims and using very simi-
lar methods of development, the final products of both teams
differ in a number of important respects (table 1). Further
development and evaluation of these tools will be undertaken
with continuing contact between the two development teams,
as there is much we can learn from each other. These are but
two examples of the expanding field of decision support tools
and decision aids.19 We predict that health care in the 21st
Table 1 Comparison of the two studies
CGP DARTs
Setting/decision Oophorectomy at time of hysterectomy Warfarin to prevent stroke in atrial fibrillation
One off decision Revocable decision
Long term outcomes Shorter term outcomes
Participants Younger women (40–55 years) Older people (men and women)
Delivered by Researcher/facilitator Responsible clinician
Value elicitation and
incorporating patient
preferences
Generic value elicitation (EuroQuol) Specific value elicitation for both outcomes + treatment health
states
Standard gamble (SG) on a single generic health state plus time
trade off (but user can opt to choose a method they prefer from
“time trade off”, SG or visual analogue scale)
Standard gamble only, values derived from each patient for all
clinically relevant health states
Opt out function to population utilities No opt out or use of population utilities
Preferences for duration of HRT treatment incorporated, but value
of treatment state (i.e. “on HRT”) not derived
Value for treatment state derived and incorporated (i.e. “on
warfarin”)
Does not seek predisposition or final treatment preference of
patient
Seeks predisposition/emerging disposition/final treatment
preference of patient
Patient alerted to types of task involved in advance to permit
prearranged opt outs
Risk assessment and
presentation
Individual risk factors elicited, incorporated into model and used
to adjust output, but patient’s individual risks of outcome events
not presented at point of elicitation of risk factors
Individual risk factors elicited and individual risks of stroke and
bleed on and off therapy made explicit to patient at the point of
elicitation of risk factors
Does not consider impact of change in other risk factors on
treatment decision (e.g. smoking/HT)
Considers impact of change in other risk factors on treatment
decision (e.g. smoking/HT)
Output Gives quantitative output in QALE and life expectancy Gives yes/no output of model
Output in the form of recommended treatment on basis of model Uses model output as but one input to inform decision
Effects of varying duration of HRT included as part of sensitivity
analysis
No sensitivity analysis
CGP=clinical guidance programme; DARTs=Decision Analysis in Routine Treatment study; HRT=hormone replacement therapy; QALE=quality adjusted
life expectancy.
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century will increasingly depend upon such supports to
enhance quality of care and the responsiveness of clinical
encounters with patients.
. . . . . . . . . . . . . . . . . . . . .
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